Charles Liam Doyle is a Formulation Scientist at Verve Therapeutics, where they currently hold a position since 2023. They transitioned to Eli Lilly and Company in 2025 as a Principal Scientist, continuing their responsibilities post-acquisition. Previously, they served as a Research Associate II at Selecta Biosciences from 2021 to 2023 and undertook various co-op positions in process development and engineering. Charles holds a Master's degree in Chemical Engineering from Northeastern University, earned in 2019.
This person is not in any teams
This person is not in any offices